☐ 1: Wiad Lek 1990 Jan 1-15;43(1-2):4-9

[Angiogenic activity of mononuclear cells in the peripheral blood of patients with ischemic heart disease]

[Article in Polish]

Pawinska M, Laniewska I, Sztorc M, Syska J, Wroblewski T, Kuch J.

Katedry i Kliniki Kardiologii II Wydzialu Lekarskiego Ak. Med., Warszawie.

In the paper the cell-mediated phase of the immune response was assessed in ischaemic heart disease (IHD). The assessment was based on the angiogenesis test in which new capillaries are formed from the already existing vascularization. The process is mediated by mononuclear cells from peripheral blood, and is induced by degradation products appearing as a result of ischaemic injury to the tissues. The test was carried out in 71 patients with IHD and in 65 clinically healthy subjects. A significant fall was demonstrated of the angiogenic activity of mononuclear cells isolated from the peripheral blood of IHD patients as compared with controls (p less than 0.001). No effect was method of disease duration, its form or treatment on angiogenesis. The obtained results may suggest a failure of the immune system competent in this process in IHD. Perhaps this is related to a special form of IHD.

PMID: 1695042 [PubMed - indexed for MEDLINE]

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1642cxy

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08  "Ask CAS" for self-help around the clock
 NEWS  3  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS  4  Apr 09  ZDB will be removed from STN
 NEWS  5  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS  6  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS  7  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS  8  Apr 22  Federal Research in Progress (FEDRIP) now available
 NEWS  9  Jun 03  New e-mail delivery for search results now available
 NEWS 10  Jun 10  MEDLINE Reload
 NEWS 11  Jun 10  PCTFULL has been reloaded
 NEWS 12  Jul 02  FOREGE no longer contains STANDARDS file segment
 NEWS 13  Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
 NEWS 14  Jul 29  Enhanced polymer searching in REGISTRY
 NEWS 15  Jul 30  NETFIRST to be removed from STN
 NEWS 16  Aug 08  CANCERLIT reload
 NEWS 17  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18  Aug 08  NTIS has been reloaded and enhanced
 NEWS 19  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
 NEWS 20  Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21  Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22  Aug 26  Sequence searching in REGISTRY enhanced
 NEWS 23  Sep 03  JAPIO has been reloaded and enhanced
 NEWS 24  Sep 16  Experimental properties added to the REGISTRY file
 NEWS 25  Sep 16  CA Section Thesaurus available in CAPLUS and CA
 NEWS 26  Oct 01  CASREACT Enriched with Reactions from 1907 to 1985
 NEWS 27  Oct 21  EVENTLINE has been reloaded
 NEWS 28  Oct 24  BEILSTEIN adds new search fields
 NEWS 29  Oct 24  Nutraceuticals International (NUTRACEUT) now available on STN
 NEWS 30  Oct 25  MEDLINE SDI run of October 8, 2002
 NEWS 31  Nov 18  DKILIT has been renamed APOLLIT
 NEWS 32  Nov 25  More calculated properties added to REGISTRY
 NEWS 33  Dec 02  TIBKAT will be removed from STN
 NEWS 34  Dec 04  CSA files on STN
 NEWS 35  Dec 17  PCTFULL now covers WP/PCT Applications from 1978 to date
 NEWS 36  Dec 17  TOXCENTER enhanced with additional content
 NEWS 37  Dec 17  Adis Clinical Trials Insight now available on STN
 NEWS 38  Dec 30  ISMEC no longer available
 NEWS 39  Jan 21  NUTRACEUT offering one free connect hour in February 2003
 NEWS 40  Jan 21  PHARMAML offering one free connect hour in February 2003
 NEWS 41  Jan 29  Simultaneous left and right truncation added to COMPENDEX,
                  ENERGY, INSPEC
 NEWS 42  Feb 13  CANCERLIT is no longer being updated
 NEWS 43  Feb 24  METADEX enhancements
 NEWS 44  Feb 24  PCTGEN now available on STN
 NEWS 45  Feb 24  TEMA now available on STN
 NEWS 46  Feb 26  NTIS now allows simultaneous left and right truncation
 NEWS 47  Feb 26  PCTFULL now contains images
 NEWS 48  Mar 04  SDI PACKAGE for monthly delivery of multifile SDI results
 NEWS 49  Mar 19  APOLLIT offering free connect time in April 2003
 NEWS 50  Mar 20  EVENTLINE will be removed from STN
 NEWS 51  Mar 24  PATDPAFULL now available on STN
 NEWS 52  Mar 24  Additional information for trade-named substances without
                  structures available in REGISTRY
 NEWS 53  Mar 24  Indexing from 1957 to 1966 added to records in CA/CAPLUS

 NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
               CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *


FILE 'HOME' ENTERED AT 14:58:10 ON 31 MAR 2003

=> file medline, cancerlit, biosis, confsci, scisearch, embase, caplus, uspatfull,
pctfull
COST IN U.S. DOLLARS                                  SINCE FILE     TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'MEDLINE' ENTERED AT 14:58:42 ON 31 MAR 2003

FILE 'CANCERLIT' ENTERED AT 14:58:42 ON 31 MAR 2003

FILE 'BIOSIS' ENTERED AT 14:58:42 ON 31 MAR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CONFSCI' ENTERED AT 14:58:42 ON 31 MAR 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'SCISEARCH' ENTERED AT 14:58:42 ON 31 MAR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'EMBASE' ENTERED AT 14:58:42 ON 31 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'CAPLUS' ENTERED AT 14:58:42 ON 31 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 14:58:42 ON 31 MAR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 14:58:42 ON 31 MAR 2003
```

COPYRIGHT (C) 2003 Univentio

=> s bone (a) marrow
L1 617302 BONE (A) MARROW

=> s l1 and mononuclear (a) cell
2 FILES SEARCHED...
6 FILES SEARCHED...
L2 23479 L1 AND MONONUCLEAR (A) CELL

=> s l2 and angiogenes?
L3 1465 L2 AND ANGIOGENES?

<------User Break------>

SEARCH ENDED BY USER

=> s l2 and vessel?
L4 2771 L2 AND VESSEL?

=> dup rem l3
PROCESSING IS APPROXIMATELY 47% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY 80% COMPLETE FOR L3
PROCESSING COMPLETED FOR L3
L5 1393 DUP REM L3 (72 DUPLICATES REMOVED)

=> s l5 not py=>2000
'2000' NOT A VALID FIELD CODE
5 FILES SEARCHED...
L6 211 L5 NOT PY=>2000

=> d 1-20

L6 ANSWER 1 OF 211 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2000:24767 BIOSIS
DN PREV200000024767
TI Local transplantation of autologous **bone marrow** -derived **mononuclear cells** augments collateral vessel formation in ischemic hindlimb in rabbits.
AU Shintani, Satoshi (1); Murohara, Toyoaki; Ueno, Takafumi; Ikeda, Hisao; Duan, Junli; Imaizumi, Tsutomu
CS (1) Kurume Univ, Kurume Japan
SO Circulation, (Nov. 2, 1999) Vol. 110, No. 18 SUPPL., pp. I.406. Meeting Info.: 72nd Scientific Sessions of the American Heart Association Atlanta, Georgia, USA November 7-10, 1999 ISSN: 0009-7322.
DT Conference
LA English

L6 ANSWER 2 OF 211 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1986:198123 BIOSIS
DN BA81:89423
TI **ANGIOGENESIS** IN ORGANIZING THROMBI NEW FINDINGS.
AU FEIGL W; LEU H J; LINTNER F; PEDIO G; SUSANI M
CS INSTITUT, ALLG. POLIKLINIK DER STADT WIEN, MARIANNENGASSE 10, A-1090 WIEN.
SO VASA, (1985 (RECD 1986)) 14 (4), 371-378. CODEN: VASAAH.
FS BA; OLD
LA German

L6 ANSWER 3 OF 211 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 2000:118869 SCISEARCH
GA The Genuine Article (R) Number: 281QJ
TI Identification of IFN-gamma-producing cells in IL-12/IL-18-treated mice
AU Otani T (Reprint); Nakamura S; Toki M; Motoda R; Kurimoto M; Orita K
CS HAYASHIBARA BIOCHEM LABS INC, FUJISAKI CELL CTR, OKAYAMA, JAPAN (Reprint); HAYASHIBARA BIOCHEM LABS INC, FUJISAKI INST, OKAYAMA, JAPAN
CYA JAPAN
SO CELLULAR IMMUNOLOGY, (15 DEC 1999) Vol. 198, No. 2, pp. 111-119. Publisher: ACADEMIC PRESS INC, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495. ISSN: 0008-8749.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 27
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L6 ANSWER 4 OF 211 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 1999:385381 SCISEARCH
GA The Genuine Article (R) Number: 195KH
TI Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: Relationship to classification and response to therapy
AU Mustjoki S (Reprint); Alitalo R; Stephens R W; Vaheri A
CS UNIV HELSINKI, HAARTMAN INST, DEPT VIROL, POB 21, FIN-00014 HELSINKI, FINLAND (Reprint); UNIV HELSINKI, HAARTMAN INST, TRANSPLANTAT LAB, FIN-00014 HELSINKI, FINLAND; UNIV HELSINKI, CENT HOSP, DEPT MED, DIV HAEMATOL, HELSINKI, FINLAND; RIGSHOSP, FINSEN INST, DK-2100 COPENHAGEN, DENMARK
CYA FINLAND; DENMARK
SO THROMBOSIS AND HAEMOSTASIS, (MAY 1999) Vol. 81, No. 5, pp. 705-710. Publisher: F K SCHATTAUER VERLAG GMBH, P O BOX 10 45 45, LENZHALDE 3, D-70040 STUTTGART, GERMANY. ISSN: 0340-6245.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 37
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L6 ANSWER 5 OF 211 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 1999:284019 SCISEARCH
GA The Genuine Article (R) Number: 183VG
TI Ischemia- and cytokine-induced mobilization of **bone marrow**-derived endothelial progenitor cells for neovascularization
AU Takahashi T; Kalka C; Masuda H; Chen D; Silver M; Kearney M; Magner M; Isner J M (Reprint); Asahara T
CS TUFTS UNIV, ST ELIZABETHS MED CTR, SCH MED, DEPT MED CARDIOL, 736 CAMBRIDGE ST, BOSTON, MA 02135 (Reprint); TUFTS UNIV, ST ELIZABETHS MED CTR, SCH MED, DEPT MED CARDIOL, BOSTON, MA 02135; TUFTS UNIV, ST ELIZABETHS MED CTR, SCH MED, DEPT BIOMED RES, BOSTON, MA 02135
CYA USA
SO NATURE MEDICINE, (APR 1999) Vol. 5, No. 4, pp. 434-438. Publisher: NATURE AMERICA INC, 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707. ISSN: 1078-8956.
DT Article; Journal
FS LIFE; CLIN
LA English
REC Reference Count: 18
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L6 ANSWER 6 OF 211 USPATFULL
AN 1999:170382 USPATFULL
TI Methods of screening for compounds that derepress or increase telomerase activity
IN West, Michael D., San Carlos, CA, United States
Harley, Calvin B., Palo Alto, CA, United States
Weinrich, Scott L., San Francisco, CA, United States
Strahl, Catherine M., San Francisco, CA, United States

McEachern, Michael J., San Francisco, CA, United States
Shay, Jerry, Dallas, TX, United States
Wright, Woodring E., Arlington, TX, United States
Blackburn, Elizabeth H., San Francisco, CA, United States
Kim, Nam Woo, Sunnyvale, CA, United States
Vaziri, Homayoun, Toronto, Canada
PA Board of Regents, The University of Texas System, Dallas, TX, United States (U.S. corporation)
The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
Geron Corporation, Menlo Park, CA, United States (U.S. corporation)
PI US 6007989 19991228
AI US 1997-819867 19970314 (8)
RLI Division of Ser. No. US 153051
DT Utility
FS Granted
LN.CNT 6145
INCL INCLM: 435/006.000
INCLS: 435/004.000; 435/007.200; 435/015.000; 435/091.200; 435/091.100; 435/375.000
NCL NCLM: 435/006.000
NCLS: 435/004.000; 435/007.200; 435/015.000; 435/091.100; 435/091.200; 435/375.000
IC [6]
ICM: C12Q001-68
ICS: C12P019-34
EXF 435/6; 435/91.2; 435/15; 435/7.1; 435/4; 435/375; 435/91.1; 935/33; 935/77; 935/78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 211 USPATFULL
AN 1999:167048 USPATFULL
TI IL-8 receptor antagonists
IN Widdowson, Katherine Louisa, King of Prussia, PA, United States
Veber, Daniel Frank, Ambler, PA, United States
Jurewicz, Anthony Joseph, Royersford, PA, United States
Hertzberg, Robert Philip, Downingtown, PA, United States
Rutledge, Jr., Melvin Clarence, Lansdale, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 6005008 19991221
WO 9625157 19960822
AI US 1997-894291 19970815 (8)
WO 1996-US2260 19960216
19970815 PCT 371 date
19970815 PCT 102(e) date
DT Utility
FS Granted
LN.CNT 4760
INCL INCLM: 514/596.000
INCLS: 514/597.000; 514/598.000; 564/048.000; 564/049.000; 564/050.000; 564/052.000
NCL NCLM: 514/596.000
NCLS: 514/597.000; 514/598.000; 564/048.000; 564/049.000; 564/050.000; 564/052.000
IC [6]
ICM: A61K031-17
ICS: C07C273-00
EXF 514/596; 514/597; 514/598; 564/48; 564/49; 564/50; 564/52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 211 USPATFULL
AN 1999:159475 USPATFULL
TI Stimulation of host defense mechanisms against tumors
IN Tovey, Michael Gerard, Paris, France
Kaido, Thomas James, San Diego, CA, United States4)
PA Pharma Pacific Pty Ltd., Brighton-Le-Sands, Australia (non-U.S. corporation)
PI US 5997858 19991207
AI US 1997-853293 19970509 (8)
PRAI AU 1996-9765 19960509
DT Utility
FS Granted
LN.CNT 987
INCL INCLM: 424/085.400
INCLS: 424/085.500; 424/085.600; 424/085.700; 424/001.110; 424/278.100; 514/002.000; 530/351.000
NCL NCLM: 424/085.400
NCLS: 424/001.110; 424/085.500; 424/085.600; 424/085.700; 424/278.100; 514/002.000; 530/351.000
IC [6]
ICM: A61K038-21
ICS: C07K014-555; C07K014-56; C07K014-57
EXF 424/85.4; 424/85.5; 424/85.6; 424/85.7; 424/1.11; 424/278.1; 514/2; 530/351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 211 USPATFULL
AN 1999:155675 USPATFULL
TI Interferon-inducible protein 10 is a potent inhibitor of **angiogenesis**
IN Tosato, Giovanna, Bethesda, MD, United States
Angiolillo, Anne L., Washington, DC, United States
Sgadari, Cecilia, Bethesda, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5994292 19991130
AI US 1995-455079 19950531 (8)
DT Utility
FS Granted
LN.CNT 1728
INCL INCLM: 514/002.000
INCLS: 514/004.000; 514/012.000; 514/021.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000
NCL NCLM: 514/002.000
NCLS: 514/004.000; 514/012.000; 514/021.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000
IC [6]
ICM: A61K038-00
EXF 514/12; 514/21; 514/214; 514/2; 514/4; 530/324; 530/300; 530/325; 530/326; 530/327; 530/328; 424/85.7; 424/85.2; 424/85.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 211 USPATFULL
AN 1999:141975 USPATFULL
TI Therapeutic inhibitor of vascular smooth muscle cells
IN Kunz, Lawrence L., Redmond, WA, United States
Klein, Richard A., Edmonds, WA, United States
Reno, John M., Brier, WA, United States
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5981568 19991109
AI US 1997-829685 19970331 (8)
RLI Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995, now patented, Pat. No. US 5811447 which is a continuation of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned And a continuation-in-part of Ser. No. WO 1996-US2125, filed on 15 Feb 1996 which is a continuation-in-part of Ser. No. US 1995-389712, filed on 15 Feb 1995
DT Utility
FS Granted

LN.CNT 5553
INCL INCLM: 514/411.000
INCLS: 514/499.000; 514/319.000; 514/324.000; 514/422.000; 514/428.000
NCL NCLM: 514/411.000
NCLS: 514/319.000; 514/324.000; 514/422.000; 514/428.000; 514/499.000
IC [6]
ICM: A61K031-40
EXF 514/499; 514/411; 514/319; 514/324; 514/422; 514/428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 211 USPATFULL
AN 1999:141637 USPATFULL
TI Polynucleotide encoding chemokine .beta.-4
IN Li, Haodong, Gaithersburg, MD, United States
Adams, Mark D., North Potomac, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 5981230 19991109
AI US 1995-458355 19950602 (8)
RLI Continuation-in-part of Ser. No. WO 1994-US9484, filed on 23 Aug 1994
DT Utility
FS Granted
LN.CNT 1648
INCL INCLM: 435/069.500
INCLS: 536/023.100; 536/023.500; 536/024.300; 536/024.310; 435/471.000; 435/325.000; 435/252.300; 435/320.100; 435/071.200; 530/324.000
NCL NCLM: 435/069.500
NCLS: 435/071.200; 435/252.300; 435/320.100; 435/325.000; 435/471.000; 530/324.000; 536/023.100; 536/023.500; 536/024.300; 536/024.310
IC [6]
ICM: C12N015-19
ICS: C12N015-63; C07K014-52
EXF 536/23.1; 536/23.5; 536/24.3; 536/24.31; 435/69.5; 435/172.3; 435/240.2; 435/240.3; 435/252.3; 435/320.1; 435/70.1; 435/71.1; 435/71.2; 435/325; 435/471; 935/11; 935/22; 935/52; 935/66; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 211 USPATFULL
AN 1999:141294 USPATFULL
TI Methods for enhancing **angiogenesis** with endothelial progenitor cells
IN Isner, Jeffrey M., Weston, MA, United States
Asahara, Takayuki, Arlington, MA, United States
PA St. Elizabeth's Medical Center of Boston, Boston, MA, United States (U.S. corporation)
PI US 5980887 19991109
AI US 1996-744882 19961108 (8)
DT Utility
FS Granted
LN.CNT 1104
INCL INCLM: 424/093.700
INCLS: 424/085.100; 424/085.200; 514/008.000; 514/044.000
NCL NCLM: 424/093.700
NCLS: 424/085.100; 424/085.200; 514/008.000; 514/044.000
IC [6]
ICM: A61K035-12
ICS: A61K048-00; A61K038-18; A61K038-19
EXF 424/93.7; 424/85.4; 424/85.2; 435/325; 435/375; 514/2; 514/8; 514/44; 530/351; 053/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 211 USPATFULL
AN 1999:117298 USPATFULL
TI Secreted proteins and polynucleotides encoding them
IN Jacobs, Kenneth, Newton, MA, United States
McCoy, John M., Reading, MA, United States
Racie, Lisa A., Acton, MA, United States
LaVallie, Edward R., Tewksbury, MA, United States
Merberg, David, Acton, MA, United States
Treacy, Maurice, Chestnut Hill, MA, United States
Evans, Cheryl, Woburn, MA, United States
PA Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5958726 19990928
AI US 1997-867680 19970602 (8)
RLI Continuation-in-part of Ser. No. US 1996-635311, filed on 19 Apr 1996
DT Utility
FS Granted
LN.CNT 1766
INCL INCLM: 435/069.100
INCLS: 435/091.100; 435/091.200; 435/091.500; 435/252.300; 435/320.100; 536/023.100; 536/023.500; 536/024.310; 530/350.000
NCL NCLM: 435/069.100
NCLS: 435/091.100; 435/091.200; 435/091.500; 435/252.300; 435/320.100; 530/350.000; 536/023.100; 536/023.500; 536/024.310
IC [6]
ICM: C12N015-00
EXF 435/69.1; 435/252.3; 435/320.1; 435/91.1; 435/91.2; 435/91.5; 536/23.1; 536/23.5; 536/24.31; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 211 USPATFULL
AN 1999:113778 USPATFULL
TI Carboxylic acid indole inhibitors of chemokines
IN Thompson, Scott K., Phoenixville, PA, United States
Halbert, Stacie M., Harleysville, PA, United States
Widdowson, Katherine L., King of Prussia, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 5955492 19990921
WO 9735572 19971002
AI US 1998-155220 19980924 (9)
WO 1997-US4938 19970327
19980924 PCT 371 date
19980924 PCT 102(e) date
PRAI US 1996-14257P 19960328 (60)
DT Utility
FS Granted
LN.CNT 1093
INCL INCLM: 514/419.000
INCLS: 514/382.000; 514/784.000; 514/826.000; 514/863.000; 548/250.000; 548/252.000; 548/254.000; 548/490.000; 548/491.000; 548/494.000; 549/440.000; 562/405.000; 562/466.000; 562/468.000
NCL NCLM: 514/419.000
NCLS: 514/382.000; 514/784.000; 514/826.000; 514/863.000; 548/250.000; 548/252.000; 548/254.000; 548/490.000; 548/491.000; 548/494.000; 549/440.000; 562/405.000; 562/466.000; 562/468.000
IC [6]
ICM: A61K031-405
ICS: C07C062-36; C07D209-18; C07D405-06
EXF 514/419; 514/784; 548/490; 548/491; 548/494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 211 USPATFULL
AN 1999:110187 USPATFULL
TI DNA encoding the chemotactic cytokine III
IN Ni, Jian, Rockville, MD, United States
Gentz, Reiner, Silver Spring, MD, United States
Yu, Guo-Liang, Darnestown, MD, United States
Su, Jeffrey, Gaithersburg, MD, United States

Dillon, Patrick J., Gaithersburg, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 5952197 19990914
AI US 1997-812003 19970305 (8)
PRAI US 1996-13609P 19960305 (60)
DT Utility
FS Granted
LN.CNT 2323
INCL INCLM: 435/069.500
INCLS: 435/069.100; 435/252.300; 435/320.100; 536/023.500; 536/024.300
NCL NCLM: 435/069.500
NCLS: 435/069.100; 435/252.300; 435/320.100; 536/023.500; 536/024.300
IC [6]
ICM: C12N015-19
ICS: C12N015-00; C12N015-63
EXF 536/23.5; 435/69.1; 435/69.5; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 211 USPATFULL
AN 1999:102965 USPATFULL
TI Mouse model of psoriasis
IN Parker, Christina M., Newton Centre, MA, United States
Schon, Michael P., Boston, MA, United States
PA Brigham & Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)
PI US 5945576 19990831
AI US 1996-628761 19960405 (8)
DT Utility
FS Granted
LN.CNT 1935
INCL INCLM: 800/009.000
INCLS: 435/375.000; 435/377.000; 424/093.700; 424/009.210
NCL NCLM: 800/009.000
NCLS: 424/009.200; 424/093.700; 435/375.000; 435/377.000
IC [6]
ICM: C12N005-00
ICS: C12N015-00; A01N063-00; A61K049-00
EXF 435/375; 435/377; 800/2; 800/DIG.5; 800/DIG.4; 800/9; 424/93.7; 424/9.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 211 USPATFULL
AN 1999:89279 USPATFULL
TI Macrophage derived chemokine and chemokine analogs
IN Godiska, Ronald, Bothell, WA, United States
Gray, Patrick W., Seattle, WA, United States
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PI US 5932703 19990803
AI US 1996-660542 19960607 (8)
RLI Continuation-in-part of Ser. No. US 1995-558658, filed on 16 Nov 1995 which is a continuation-in-part of Ser. No. US 1995-479620, filed on 7 Jun 1995
DT Utility
FS Granted
LN.CNT 2745
INCL INCLM: 530/351.000
INCLS: 530/324.000; 930/140.000; 424/085.100
NCL NCLM: 530/351.000
NCLS: 424/085.100; 530/324.000; 930/140.000
IC [6]
ICM: C07K014-52
ICS: A61K038-19
EXF 530/351; 530/324; 930/140; 424/85.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 211 USPATFULL
AN 1999:85601 USPATFULL
TI IL-8 receptor antagonists
IN Widdowson, Katherine L., King Prussia, PA, United States
Nie, Hong, Conshohocken, PA, United States
Rutledge, Jr., Melvin Clarence, Thousand Oaks, CA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 5929250 19990727
AI US 1998-121264 19980723 (9)
RLI Continuation-in-part of Ser. No. WO 1998-US1292, filed on 23 Jan 1998
PRAI US 1997-42830P 19970408 (60)
US 1997-35990P 19970123 (60)
DT Utility
FS Granted
LN.CNT 1462
INCL INCLM: 548/361.100
INCLS: 514/403.000
NCL NCLM: 548/361.100
IC [6]
ICM: A61K031-415
ICS: C07D231-56
EXF 548/361.1; 514/403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 211 USPATFULL
AN 1999:85471 USPATFULL
TI Guainidino, formamidino, amino and related compounds for inhibiting osteoclast-mediated bone resorption
IN Hartman, George D., Lansdale, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Hoffman, William F., Lansdale, PA, United States
Ihle, Nathan C., Mercer Island, WA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5929120 19990727
AI US 1998-15982 19980130 (9)
RLI Division of Ser. No. US 1996-714097, filed on 26 Sep 1996, now patented, Pat. No. US 5741796 which is a continuation-in-part of Ser. No. US 1994-250218, filed on 27 May 1994, now abandoned
DT Utility
FS Granted
LN.CNT 3417
INCL INCLM: 514/634.000
INCLS: 514/567.000; 514/568.000; 514/619.000; 562/430.000; 562/439.000; 564/084.000; 564/170.000; 564/246.000; 564/247.000
NCL NCLM: 514/634.000
NCLS: 514/567.000; 514/568.000; 514/619.000; 562/430.000; 562/439.000; 564/084.000; 564/170.000; 564/246.000; 564/247.000
IC [6]
ICM: A61K031-155
ICS: A61K031-19; C07C257-10; C07C307-02
EXF 514/256; 514/300; 514/311; 514/567; 514/568; 514/619; 514/634; 544/332; 544/333; 546/164; 546/176; 546/177; 546/268.1; 546/290; 546/304; 562/430; 562/439; 564/84; 564/170; 564/246; 564/247
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 211 USPATFULL
AN 1999:65188 USPATFULL
TI Polynucleotides encoding chemokine .alpha.-2
IN Ni, Jian, Rockville, MD, United States
Gentz, Reiner L., Silver Spring, MD, United States
Su, Jeffrey Y., Gaithersburg, MD, United States
Li, Haodong, Gaithersburg, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

```
PI      US 5910431              19990608
AI      US 1997-825556          19970319 (8)
DT      Utility
FS      Granted
LN.CNT 2491
INCL    INCLM: 435/069.500
        INCLS: 435/252.300; 435/320.100; 536/023.500; 536/024.300; 536/024.330
NCL     NCLM:  435/069.500
        NCLS:  435/252.300; 435/320.100; 536/023.500; 536/024.300; 536/024.330
IC      [6]
        ICM: C12N001-00
        ICS: C12N015-00
EXF     536/23.5; 536/24.3-24.33; 435/69.5; 435/752.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=>

---Logging off of STN---


=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                  ENTRY     SESSION
FULL ESTIMATED COST                               73.54       73.75

STN INTERNATIONAL LOGOFF AT 15:20:50 ON 31 MAR 2003
```

WEST

End of Result Set

102 e Art?

☐ Generate Collection Print

L1: Entry 1 of 1 File: USPT Nov 9, 1999

US-PAT-NO: 5980887
DOCUMENT-IDENTIFIER: US 5980887 A

TITLE: Methods for enhancing angiogenesis with endothelial progenitor cells

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Isner; Jeffrey M.	Weston	MA		
Asahara; Takayuki	Arlington	MA		

US-CL-CURRENT: 424/93.7; 424/85.1, 424/85.2, 514/44, 514/8

CLAIMS:

What is claimed is:

1. A method for inducing the formation of new blood vessels in an ischemic tissue in a patient in need thereof, comprising:

administering to said patient host an effective amount of an isolated endothelial progenitor cell to induce new blood vessel formation in said ischemic tissue, wherein said endothelial progenitor cell are CD34.sup.+, flk-1.sup.+ or tie-2.sup.+.

2. The method of claim 1, further comprising the step of administering to the patient an endothelial cell mitogen or a nucleic acid encoding an endothelial cell mitogen.

3. The method of claim 2, wherein the endothelial cell mitogen is selected from the group consisting of acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor a and .beta., platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor .alpha., hepatocyte growth factor, insulin like growth factor, erythropoietin, colony stimulating factor, macrophage-CSF, granulocyte/macrophage CSF and nitric oxidesynthase.

4. The method of claim 3, wherein the endothelial cell mitogen is vascular endothelial growth factor.

5. The method of claim 1, wherein said patient is in need of treatment for cerebrovascular ischemia, renal ischemia, pulmonary ischemia, limb ischemia, ischemic cardiomyopathy and myocardial ischemia.

6. A method of enhancing blood vessel formation in a patient in need thereof, comprising:

a. selecting the patient in need thereof;

b. isolating endothelial progenitor cells from the patient, wherein said endothelial progenitor cell are CD34.sup.+, flk-1.sup.+ or tie-2.sup.+ ; and

c. readministering the endothelial progenitor cells to the patient.

7. A method for treating an injured blood vessel in a patient in need thereof, comprising:

a. selecting the patient in need thereof; and

b. isolating endothelial progenitor cells from the patient, wherein said endothelial progenitor cell are CD34.sup.+, flk-1.sup.+ or tie-2.sup.+ ; and

c. readministering the endothelial progenitor cells to the patient.

8. The method of claim 7, wherein the injury is the result of balloon angioplasty.

9. The method of claim 7, wherein the injury is the result of deployment of an endovascular stent.

10. The method of claim 7, further comprising the step of administering to the patient an endothelial cell mitogen or a nucleic acid encoding an endothelial cell mitogen.

11. The method of claim 10, wherein the endothelial cell mitogen is selected from the group consisting of acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor a and .beta., platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor .alpha., hepatocyte growth factor, insulin like growth factor, erythropoietin, colony stimulating factor, macrophage-CSF, granulocyte/macrophage CSF and nitric oxidesynthase.